Physician profile
Gregory S Riggs
NPI 1962667675
$3,064.30
in general payments reported to CMS, 2019-2025
36 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $356 · 2021: $289 · 2022: $379 · 2023: $527 · 2024: $530 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $381.06 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $340.38 | 2021-2024 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $323.63 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $272.62 | 2019-2025 | |
| Lilly USA, LLC | $268.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $171.12 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $137.40 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.71 | 2020-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $92.37 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $71.11 | 2019-2025 | Zoryve |
| Exact Sciences Corporation | $66.77 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $64.79 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.92 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $52.16 | 2019-2020 | |
| Amarin Pharma, INC. | $49.69 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $47.04 | 2022-2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $43.70 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.68 | 2021 | |
| Seqirus USA INC | $41.54 | 2019-2024 | Fluad, Flucelvax |
| Allergan, INC. | $40.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $38.05 | 2019-2025 | Austedo Xr |
| Dexcom, INC. | $32.93 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $32.54 | 2024-2025 | Voquezna |
| Noven Therapeutics, LLC | $32.38 | 2023-2024 | Xelstrym |
| Sanofi Pasteur INC. | $24.41 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $20.74 | 2019 | |
| Lundbeck LLC | $19.60 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $18.65 | 2025 | Rexulti |
| Ardelyx, INC. | $18.44 | 2025 | Ibsrela |
| Eisai INC. | $17.22 | 2021 | |
| Genentech USA, INC. | $15.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.64 | 2021 | |
| Verona Pharma, INC. | $14.06 | 2025 | Ohtuvayre |
| Acella Pharmaceuticals, LLC | $13.84 | 2024 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Riggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.